NCT05715229View on ClinicalTrials.gov

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

April 28, 2026

Study Completion Date

April 28, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Nivolumab

Immunotherapy

DRUG

Ipilimumab

Immunotherapy

DRUG

Carboplatin

Chemotherapy

DRUG

Paclitaxel

Chemotherapy

DRUG

Pemetrexed

Chemotherapy

Trial Locations (3)

20007

NOT_YET_RECRUITING

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

07410

RECRUITING

John Theurer Cancer Center, Hackensack Meridian Health, Hackensack

07753

NOT_YET_RECRUITING

Jersey Shore University Medical Center, Neptune City

All Listed Sponsors
collaborator

MedSIR

OTHER

lead

Hackensack Meridian Health

OTHER